Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28366701 | 0.80 | CSNK2A2 (0.41) | P2RX7HCAR2TTRLMNACSNK2A2 | |
| SCHEMBL7118321 | 0.78 | P2RX7 (0.39) | P2RX7HCAR2TTRHDAC1KCNH2 | |
| SCHEMBL1779055 | 0.73 | TTR (0.41) | P2RX7HCAR2TTRHDAC1KCNH2 | |
| SCHEMBL27814650 | 0.71 | TTR (0.46) | P2RX7HCAR2TTRLMNAHDAC1 | |
| Hydrochloric Acid SCHEMBL5287806 | 0.71 | P2RX7 (0.36) | P2RX7HCAR2TTRKCNH2 | |
| SCHEMBL28628018 | 0.69 | HCAR2 (0.67) | HCAR2 | |
| SCHEMBL12486045 | 0.68 | HCAR2 (0.42) | P2RX7HCAR2TTRKCNH2 | |
| SCHEMBL27152639 | 0.67 | HCAR2 (0.39) | P2RX7HCAR2TTRKCNH2 | |
| SCHEMBL11203864 | 0.67 | HCAR2 (0.44) | P2RX7HCAR2TTR | |
| SCHEMBL5552192 | 0.66 | HCAR2 (0.43) | P2RX7HCAR2TTRDPP4DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040700-B1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009074519-A1 | COMBINATIONS OF PYRAZOLYL OR ISOXAZOLYL P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| EP-2040700-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007141267-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885HCAR2 86/4885TTR 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.